Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
Petra Hoever, Georg Dorffner, Heike Beneš, et al.
Clinical Pharmacology & Therapeutics (2012) Vol. 91, Iss. 6, pp. 975-985
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Orexin receptor antagonism for treatment of insomnia
W. Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Neurology (2012) Vol. 79, Iss. 23, pp. 2265-2274
Closed Access | Times Cited: 298
Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination
Markku Partinen, Birgitte Rahbek Kornum, Giuseppe Plazzi, et al.
The Lancet Neurology (2014) Vol. 13, Iss. 6, pp. 600-613
Closed Access | Times Cited: 254
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Guidelines for the Recording and Evaluation of Pharmaco-EEG Data in Man: The International Pharmaco-EEG Society (IPEG)
Marc Jobert, Frederick J. Wilson, G.S.F. Ruigt, et al.
Neuropsychobiology (2012) Vol. 66, Iss. 4, pp. 201-220
Open Access | Times Cited: 170
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Physiology of the orexinergic/hypocretinergic system: a revisit in 2012
Jyrki P. Kukkonen
AJP Cell Physiology (2012) Vol. 304, Iss. 1, pp. C2-C32
Closed Access | Times Cited: 133
Objective prevalence of insomnia in the São Paulo, Brazil epidemiologic sleep study
Laura Castro, Dalva Poyares, Damien Léger, et al.
Annals of Neurology (2013) Vol. 74, Iss. 4, pp. 537-546
Closed Access | Times Cited: 122
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi, Ying Zhang, Saheeda Jackson, et al.
Cephalalgia (2014) Vol. 35, Iss. 5, pp. 379-388
Closed Access | Times Cited: 103
Orexins and fear: implications for the treatment of anxiety disorders
África Flores, Rocío Saravia, Rafaël Maldonado, et al.
Trends in Neurosciences (2015) Vol. 38, Iss. 9, pp. 550-559
Open Access | Times Cited: 92
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Neuropeptides and Neuropeptide Receptors: Drug Targets, and Peptide and Non‐Peptide Ligands: a Tribute to Prof. Dieter Seebach
Daniël Hoyer, Tamás Bartfai
Chemistry & Biodiversity (2012) Vol. 9, Iss. 11, pp. 2367-2387
Open Access | Times Cited: 98
Orexin (Hypocretin) Receptor Agonists and Antagonists for Treatment of Sleep Disorders
Michihiro Mieda, Takeshi Sakurai
CNS Drugs (2013) Vol. 27, Iss. 2, pp. 83-90
Closed Access | Times Cited: 98
The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors
Géraldine M. Mang, Thomas Dürst, Hugo Bürki, et al.
SLEEP (2012) Vol. 35, Iss. 12, pp. 1625-1635
Open Access | Times Cited: 92
The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry
Quanhui Chen, Luı́s de Lecea, Zhian Hu, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 152-197
Closed Access | Times Cited: 79
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
Anthony L. Gotter, Mark S. Forman, C. Meacham Harrell, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 72
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Open Access | Times Cited: 65
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data
Ellen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Sleep Medicine (2015) Vol. 19, pp. 93-100
Closed Access | Times Cited: 64
Page 1 - Next Page

Scroll to top